ANC 0 3 0 3 B-clinical_variable
> 4 5 4 5 O
= 5 6 5 6 O
1000 7 11 7 11 B-lower_bound
/ 11 12 11 12 I-lower_bound
mcL 12 15 12 15 I-lower_bound

Absolute 0 8 16 24 B-clinical_variable
CD4 9 12 25 28 I-clinical_variable
count 13 18 29 34 I-clinical_variable
> 19 20 35 36 O
100 21 24 37 40 B-lower_bound
cells 25 30 41 46 I-lower_bound
/ 30 31 46 47 I-lower_bound
uL 31 33 47 49 I-lower_bound

Absolute 0 8 50 58 B-clinical_variable
neutrophil 9 19 59 69 I-clinical_variable
count 20 25 70 75 I-clinical_variable
( 26 27 76 77 I-clinical_variable
ANC 27 30 77 80 I-clinical_variable
) 30 31 80 81 I-clinical_variable
> 32 33 82 83 O
= 33 34 83 84 O
1,500 35 40 85 90 B-lower_bound
/ 40 41 90 91 I-lower_bound
mcL 41 44 91 94 I-lower_bound

Advanced 0 8 95 103 O
stage 9 14 104 109 O
cutaneous 15 24 110 119 B-cancer
T 25 26 120 121 I-cancer
- 26 27 121 122 I-cancer
cell 27 31 122 126 I-cancer
lymphoma 32 40 127 135 I-cancer
( 41 42 136 137 I-cancer
CTCL 42 46 137 141 I-cancer
) 46 47 141 142 I-cancer
, 47 48 142 143 O
specifically 49 61 144 156 O
CTCL 62 66 157 161 O
NOS 67 70 162 165 O
, 70 71 165 166 O
small 72 77 167 172 B-cancer
/ 77 78 172 173 I-cancer
medium 78 84 173 179 I-cancer
T 85 86 180 181 I-cancer
- 86 87 181 182 I-cancer
cell 87 91 182 186 I-cancer
lymphoma 92 100 187 195 I-cancer
( 101 102 196 197 I-cancer
SMTCL 102 107 197 202 I-cancer
) 107 108 202 203 I-cancer
and 109 112 204 207 O
mycosis 113 120 208 215 B-chronic_disease
fungoides 121 130 216 225 I-chronic_disease
( 131 132 226 227 I-chronic_disease
MF 132 134 227 229 I-chronic_disease
) 134 135 229 230 I-chronic_disease
stage 136 141 231 236 O
IB 142 144 237 239 O
, 144 145 239 240 O
IIA 146 149 241 244 O
, 149 150 244 245 O
IIB 151 154 246 249 O
, 154 155 249 250 O
III 156 159 251 254 O
and 160 163 255 258 O
IV 164 166 259 261 O
that 167 171 262 266 O
have 172 176 267 271 O
relapsed 177 185 272 280 O
after 186 191 281 286 O
at 192 194 287 289 O
least 195 200 290 295 O
one 201 204 296 299 B-lower_bound
specific 205 213 300 308 O
prior 214 219 309 314 B-treatment
therapy 220 227 315 322 I-treatment
( 228 229 323 324 O
e.g. 229 233 324 328 O
interferon 234 244 329 339 B-treatment
, 244 245 339 340 O
photopheresis 246 259 341 354 B-treatment
, 259 260 354 355 O
denileukin 261 271 356 366 B-treatment
difitox 272 279 367 374 I-treatment
, 279 280 374 375 O
bexarotene 281 291 376 386 B-treatment
, 291 292 386 387 O
etc 293 296 388 391 O
) 296 297 391 392 O
; 297 298 392 393 O
anaplastic 299 309 394 404 B-cancer
cutaneous 310 319 405 414 I-cancer
large 320 325 415 420 I-cancer
cell 326 330 421 425 I-cancer
lymphoma 331 339 426 434 I-cancer
( 340 341 435 436 I-cancer
ACLCL 341 346 436 441 I-cancer
) 346 347 441 442 I-cancer
and 348 351 443 446 O
lymphomatoid 352 364 447 459 B-chronic_disease
papulopsis 365 375 460 470 I-chronic_disease

All 0 3 471 474 O
potential 4 13 475 484 O
patients 14 22 485 493 O
must 23 27 494 498 O
undergo 28 35 499 506 O
a 36 37 507 508 O
tuberculosis 38 50 509 521 B-chronic_disease
( 51 52 522 523 I-chronic_disease
TB 52 54 523 525 I-chronic_disease
) 54 55 525 526 I-chronic_disease
test 56 60 527 531 O
prior 61 66 532 537 O
to 67 69 538 540 O
study 70 75 541 546 O
entry 76 81 547 552 O
to 82 84 553 555 O
rule 85 89 556 560 O
out 90 93 561 564 O
active 94 100 565 571 B-chronic_disease
or 101 103 572 574 O
latent 104 110 575 581 B-chronic_disease
tuberculosis 111 123 582 594 I-chronic_disease
( 124 125 595 596 O
either 125 131 596 602 O
purified 132 140 603 611 O
protein 141 148 612 619 O
derivative 149 159 620 630 O
[ 160 161 631 632 O
PPD 161 164 632 635 O
] 164 165 635 636 O
or 166 168 637 639 O
QuantiFERON 169 180 640 651 O
- 180 181 651 652 O
TB 181 183 652 654 O
Gold 184 188 655 659 O
, 188 189 659 660 O
whichever 190 199 661 670 O
is 200 202 671 673 O
preferred 203 212 674 683 O
and 213 216 684 687 O
available 217 226 688 697 O
at 227 229 698 700 O
the 230 233 701 704 O
institution 234 245 705 716 O
) 245 246 716 717 O
; 246 247 717 718 O
patients 248 256 719 727 O
with 257 261 728 732 O
a 262 263 733 734 O
history 264 271 735 742 O
of 272 274 743 745 O
TB 275 277 746 748 O
( 278 279 749 750 O
even 279 283 750 754 O
if 284 286 755 757 O
treated 287 294 758 765 O
) 294 295 765 766 O
, 295 296 766 767 O
or 297 299 768 770 O
evidence 300 308 771 779 O
of 309 311 780 782 O
active 312 318 783 789 O
or 319 321 790 792 O
latent 322 328 793 799 B-chronic_disease
TB 329 331 800 802 I-chronic_disease
, 331 332 802 803 O
are 333 336 804 807 O
excluded 337 345 808 816 O
; 345 346 816 817 O
the 347 350 818 821 O
diagnosis 351 360 822 831 O
of 361 363 832 834 O
active 364 370 835 841 B-chronic_disease
TB 371 373 842 844 I-chronic_disease
is 374 376 845 847 O
defined 377 384 848 855 O
per 385 388 856 859 O
current 389 396 860 867 O
guidelines 397 407 868 878 O
; 407 408 878 879 O
patients 409 417 880 888 O
with 418 422 889 893 O
a 423 424 894 895 O
positive 425 433 896 904 O
TB 434 436 905 907 O
test 437 441 908 912 O
( 442 443 913 914 O
e.g. 443 447 914 918 O
PPD 448 451 919 922 O
or 452 454 923 925 O
QuantiFERON 455 466 926 937 O
- 466 467 937 938 O
TB 467 469 938 940 O
Gold 470 474 941 945 O
) 474 475 945 946 O
will 476 480 947 951 O
be 481 483 952 954 O
excluded 484 492 955 963 O
; 492 493 963 964 O
patients 494 502 965 973 O
with 503 507 974 978 O
history 508 515 979 986 O
of 516 518 987 989 O
Bacille 519 526 990 997 B-treatment
- 526 527 997 998 I-treatment
Calmette 527 535 998 1006 I-treatment
- 535 536 1006 1007 I-treatment
Guerin 536 542 1007 1013 I-treatment
( 543 544 1014 1015 I-treatment
BCG 544 547 1015 1018 I-treatment
) 547 548 1018 1019 I-treatment
vaccination 549 560 1020 1031 O
will 561 565 1032 1036 O
be 566 568 1037 1039 O
tested 569 575 1040 1046 O
with 576 580 1047 1051 O
QuantiFERON 581 592 1052 1063 O
- 592 593 1063 1064 O
TB 593 595 1064 1066 O
Gold 596 600 1067 1071 O
test 601 605 1072 1076 O
in 606 608 1077 1079 O
order 609 614 1080 1085 O
to 615 617 1086 1088 O
rule 618 622 1089 1093 O
out 623 626 1094 1097 O
exposure 627 635 1098 1106 O
to 636 638 1107 1109 O
TB 639 641 1110 1112 O

Any 0 3 1113 1116 O
history 4 11 1117 1124 O
or 12 14 1125 1127 O
evidence 15 23 1128 1136 O
of 24 26 1137 1139 O
opportunistic 27 40 1140 1153 O
infection 41 50 1154 1163 O
within 51 57 1164 1170 O
6 58 59 1171 1172 B-upper_bound
months 60 66 1173 1179 I-upper_bound
of 67 69 1180 1182 O
screening 70 79 1183 1192 O
including 80 89 1193 1202 O
tuberculosis 90 102 1203 1215 B-chronic_disease
, 102 103 1215 1216 O
severe 104 110 1217 1223 O
cytomegalovirus 111 126 1224 1239 B-chronic_disease
( 127 128 1240 1241 I-chronic_disease
CMV 128 131 1241 1244 I-chronic_disease
) 131 132 1244 1245 I-chronic_disease
or 133 135 1246 1248 O
herpetic 136 144 1249 1257 B-chronic_disease
infections 145 155 1258 1268 I-chronic_disease
( 156 157 1269 1270 O
such 157 161 1270 1274 O
as 162 164 1275 1277 O
disseminated 165 177 1278 1290 B-chronic_disease
herpes 178 184 1291 1297 I-chronic_disease
, 184 185 1297 1298 O
herpes 186 192 1299 1305 B-chronic_disease
encephalitis 193 205 1306 1318 I-chronic_disease
, 205 206 1318 1319 O
ophthalmic 207 217 1320 1330 B-chronic_disease
herpes 218 224 1331 1337 I-chronic_disease
) 224 225 1337 1338 O

Aspartate 0 9 1339 1348 B-clinical_variable
aminotransferase 10 26 1349 1365 I-clinical_variable
( 27 28 1366 1367 I-clinical_variable
AST 28 31 1367 1370 I-clinical_variable
) 31 32 1370 1371 I-clinical_variable
( 33 34 1372 1373 O
serum 34 39 1373 1378 B-clinical_variable
glutamic 40 48 1379 1387 I-clinical_variable
oxaloacetic 49 60 1388 1399 I-clinical_variable
transaminase 61 73 1400 1412 I-clinical_variable
[ 74 75 1413 1414 I-clinical_variable
SGOT])/alanine 75 89 1414 1428 I-clinical_variable
aminotransferase 90 106 1429 1445 I-clinical_variable
( 107 108 1446 1447 I-clinical_variable
ALT 108 111 1447 1450 I-clinical_variable
) 111 112 1450 1451 I-clinical_variable
( 113 114 1452 1453 O
serum 114 119 1453 1458 B-clinical_variable
glutamic 120 128 1459 1467 I-clinical_variable
pyruvic 129 136 1468 1475 I-clinical_variable
transaminase 137 149 1476 1488 I-clinical_variable
[ 150 151 1489 1490 I-clinical_variable
SGPT 151 155 1490 1494 I-clinical_variable
] 155 156 1494 1495 I-clinical_variable
) 156 157 1495 1496 O
= 158 159 1497 1498 O
< 159 160 1498 1499 O
2.5 161 164 1500 1503 B-upper_bound
x 165 166 1504 1505 I-upper_bound
institutional 167 180 1506 1519 I-upper_bound
upper 181 186 1520 1525 I-upper_bound
limit 187 192 1526 1531 I-upper_bound
of 193 195 1532 1534 I-upper_bound
normal 196 202 1535 1541 I-upper_bound

At 0 2 1542 1544 O
least 3 8 1545 1550 O
14 9 11 1551 1553 B-lower_bound
days 12 16 1554 1558 I-lower_bound
from 17 21 1559 1563 O
the 22 25 1564 1567 O
last 26 30 1568 1572 B-treatment
therapy 31 38 1573 1580 I-treatment
dose 39 43 1581 1585 I-treatment
or 44 46 1586 1588 O
5 47 48 1589 1590 B-lower_bound
half 49 53 1591 1595 I-lower_bound
- 53 54 1595 1596 I-lower_bound
lives 54 59 1596 1601 I-lower_bound
( 60 61 1602 1603 O
whichever 61 70 1603 1612 O
is 71 73 1613 1615 O
shorter 74 81 1616 1623 O
) 81 82 1623 1624 O
, 82 83 1624 1625 O
and 84 87 1626 1629 O
resolution 88 98 1630 1640 O
of 99 101 1641 1643 O
toxicity 102 110 1644 1652 O
related 111 118 1653 1660 O
to 119 121 1661 1663 O
the 122 125 1664 1667 O
last 126 130 1668 1672 O
therapy 131 138 1673 1680 O
, 138 139 1680 1681 O
excluding 140 149 1682 1691 O
grade 150 155 1692 1697 B-upper_bound
2 156 157 1698 1699 I-upper_bound
or 158 160 1700 1702 O
less 161 165 1703 1707 O
peripheral 166 176 1708 1718 B-chronic_disease
neuropathy 177 187 1719 1729 I-chronic_disease
and 188 191 1730 1733 O
alopecia 192 200 1734 1742 B-chronic_disease
; 200 201 1742 1743 O
for 202 205 1744 1747 O
radiation 206 215 1748 1757 B-treatment
therapy 216 223 1758 1765 I-treatment
, 223 224 1765 1766 O
a 225 226 1767 1768 O
minimum 227 234 1769 1776 O
of 235 237 1777 1779 O
2 238 239 1780 1781 B-lower_bound
weeks 240 245 1782 1787 I-lower_bound
and 246 249 1788 1791 O
resolution 250 260 1792 1802 O
of 261 263 1803 1805 O
all 264 267 1806 1809 O
acute 268 273 1810 1815 O
toxicity 274 282 1816 1824 O
will 283 287 1825 1829 O
be 288 290 1830 1832 O
required 291 299 1833 1841 O

Confirmed 0 9 1842 1851 O
diagnosis 10 19 1852 1861 O
of 20 22 1862 1864 O
peripheral 23 33 1865 1875 B-cancer
T 34 35 1876 1877 I-cancer
- 35 36 1877 1878 I-cancer
cell 36 40 1878 1882 I-cancer
lymphoma 41 49 1883 1891 I-cancer
( 50 51 1892 1893 I-cancer
PTCL 51 55 1893 1897 I-cancer
) 55 56 1897 1898 I-cancer
or 57 59 1899 1901 O
angioimmunoblastic 60 78 1902 1920 B-cancer
T 79 80 1921 1922 I-cancer
- 80 81 1922 1923 I-cancer
cell 81 85 1923 1927 I-cancer
lymphoma 86 94 1928 1936 I-cancer
( 95 96 1937 1938 I-cancer
AITL 96 100 1938 1942 I-cancer
) 100 101 1942 1943 I-cancer
that 102 106 1944 1948 O
is 107 109 1949 1951 O
refractory 110 120 1952 1962 O
to 121 123 1963 1965 O
at 124 126 1966 1968 O
least 127 132 1969 1974 O
one 133 136 1975 1978 B-lower_bound
line 137 141 1979 1983 B-treatment
of 142 144 1984 1986 I-treatment
therapy 145 152 1987 1994 I-treatment

Creatinine 0 10 1995 2005 B-clinical_variable
< 11 12 2006 2007 O
1.5 13 16 2008 2011 B-upper_bound
mg 17 19 2012 2014 I-upper_bound
/ 19 20 2014 2015 I-upper_bound
dl 20 22 2015 2017 I-upper_bound
(= 23 25 2018 2020 O
132 26 29 2021 2024 O
umol 30 34 2025 2029 O
/ 34 35 2029 2030 O
L 35 36 2030 2031 O
) 36 37 2031 2032 O

Creatinine 0 10 2033 2043 B-clinical_variable
clearance 11 20 2044 2053 I-clinical_variable
> 21 22 2054 2055 O
= 22 23 2055 2056 O
50 24 26 2057 2059 B-lower_bound
mL 27 29 2060 2062 I-lower_bound
/ 29 30 2062 2063 I-lower_bound
min/1.73 30 38 2063 2071 I-lower_bound
m^2 39 42 2072 2075 I-lower_bound
for 43 46 2076 2079 O
patients 47 55 2080 2088 O
with 56 60 2089 2093 O
creatinine 61 71 2094 2104 O
levels 72 78 2105 2111 O
above 79 84 2112 2117 O
institutional 85 98 2118 2131 O
normal 99 105 2132 2138 O

Eastern 0 7 2139 2146 B-clinical_variable
Cooperative 8 19 2147 2158 I-clinical_variable
Oncology 20 28 2159 2167 I-clinical_variable
Group 29 34 2168 2173 I-clinical_variable
( 35 36 2174 2175 I-clinical_variable
ECOG 36 40 2175 2179 I-clinical_variable
) 40 41 2179 2180 I-clinical_variable
performance 42 53 2181 2192 I-clinical_variable
status 54 60 2193 2199 I-clinical_variable
= 61 62 2200 2201 O
< 62 63 2201 2202 O
2 64 65 2203 2204 B-upper_bound
( 66 67 2205 2206 O
Karnofsky 67 76 2206 2215 B-clinical_variable
> 77 78 2216 2217 O
= 78 79 2217 2218 O
60 80 82 2219 2221 B-lower_bound
% 82 83 2221 2222 I-lower_bound
) 83 84 2222 2223 O

Euthyroid 0 9 2224 2233 O
participants 10 22 2234 2246 O
with 23 27 2247 2251 O
a 28 29 2252 2253 O
history 30 37 2254 2261 O
of 38 40 2262 2264 O
Grave 41 46 2265 2270 B-chronic_disease
's 46 48 2270 2272 I-chronic_disease
disease 49 56 2273 2280 I-chronic_disease
( 57 58 2281 2282 O
participants 58 70 2282 2294 O
suspected 71 80 2295 2304 O
autoimmune 81 91 2305 2315 O
thyroid 92 99 2316 2323 O
disorders 100 109 2324 2333 O
must 110 114 2334 2338 O
be 115 117 2339 2341 O
negative 118 126 2342 2350 O
for 127 130 2351 2354 O
thyroglobulin 131 144 2355 2368 O
and 145 148 2369 2372 O
thyroid 149 156 2373 2380 O
peroxidase 157 167 2381 2391 O
antibodies 168 178 2392 2402 O
and 179 182 2403 2406 O
thyroid 183 190 2407 2414 O
stimulating 191 202 2415 2426 O
immunoglobulin 203 217 2427 2441 O
prior 218 223 2442 2447 O
to 224 226 2448 2450 O
first 227 232 2451 2456 O
dose 233 237 2457 2461 O
of 238 240 2462 2464 O
study 241 246 2465 2470 B-treatment
drug 247 251 2471 2475 I-treatment
) 251 252 2475 2476 O

Evidence 0 8 2477 2485 O
of 9 11 2486 2488 O
active 12 18 2489 2495 B-chronic_disease
infection 19 28 2496 2505 I-chronic_disease
by 29 31 2506 2508 O
hepatitis 32 41 2509 2518 B-chronic_disease
B 42 43 2519 2520 I-chronic_disease
and/or 44 50 2521 2527 I-chronic_disease
C 51 52 2528 2529 I-chronic_disease
; 52 53 2529 2530 O
active 54 60 2531 2537 B-chronic_disease
viral 61 66 2538 2543 I-chronic_disease
infection 67 76 2544 2553 I-chronic_disease
by 77 79 2554 2556 O
hepatitis 80 89 2557 2566 O
B 90 91 2567 2568 O
and 92 95 2569 2572 O
hepatitis 96 105 2573 2582 B-chronic_disease
C 106 107 2583 2584 I-chronic_disease
could 108 113 2585 2590 O
be 114 116 2591 2593 O
associated 117 127 2594 2604 O
with 128 132 2605 2609 O
cytopenias 133 143 2610 2620 B-chronic_disease
( 144 145 2621 2622 O
due 145 148 2622 2625 O
to 149 151 2626 2628 O
hypersplenism 152 165 2629 2642 B-chronic_disease
or 166 168 2643 2645 O
due 169 172 2646 2649 O
to 173 175 2650 2652 O
the 176 179 2653 2656 O
active 180 186 2657 2663 O
virus 187 192 2664 2669 O
itself 193 199 2670 2676 O
) 199 200 2676 2677 O
, 200 201 2677 2678 O
which 202 207 2679 2684 O
could 208 213 2685 2690 O
add 214 217 2691 2694 O
further 218 225 2695 2702 O
risk 226 230 2703 2707 O
when 231 235 2708 2712 O
a 236 237 2713 2714 O
potential 238 247 2715 2724 O
immunosuppressive 248 265 2725 2742 B-treatment
medication 266 276 2743 2753 I-treatment
is 277 279 2754 2756 O
used 280 284 2757 2761 O
; 284 285 2761 2762 O
for 286 289 2763 2766 O
patients 290 298 2767 2775 O
with 299 303 2776 2780 O
hepatitis 304 313 2781 2790 O
B 314 315 2791 2792 O
treated 316 323 2793 2800 O
with 324 328 2801 2805 O
anti 329 333 2806 2810 B-treatment
- 333 334 2810 2811 I-treatment
virals 334 340 2811 2817 I-treatment
to 341 343 2818 2820 O
undetectable 344 356 2821 2833 O
viral 357 362 2834 2839 B-clinical_variable
load 363 367 2840 2844 I-clinical_variable
, 367 368 2844 2845 O
and 369 372 2846 2849 O
for 373 376 2850 2853 O
patients 377 385 2854 2862 O
with 386 390 2863 2867 O
hepatitis 391 400 2868 2877 O
C 401 402 2878 2879 O
with 403 407 2880 2884 O
undetectable 408 420 2885 2897 O
ribonucleic 421 432 2898 2909 O
acid 433 437 2910 2914 O
( 438 439 2915 2916 O
RNA 439 442 2916 2919 O
) 442 443 2919 2920 O
levels 444 450 2921 2927 O
and 451 454 2928 2931 O
no 455 457 2932 2934 O
evidence 458 466 2935 2943 O
of 467 469 2944 2946 O
liver 470 475 2947 2952 O
damage 476 482 2953 2959 O
, 482 483 2959 2960 O
enrollment 484 494 2961 2971 O
may 495 498 2972 2975 O
be 499 501 2976 2978 O
considered 502 512 2979 2989 O

Follicular 0 10 2990 3000 B-cancer
lymphoma 11 19 3001 3009 I-cancer
grade 20 25 3010 3015 B-lower_bound
1 26 27 3016 3017 I-lower_bound
, 27 28 3017 3018 O
2 29 30 3019 3020 O
or 31 33 3021 3023 O
3A 34 36 3024 3026 B-upper_bound
that 37 41 3027 3031 O
meets 42 47 3032 3037 O
the 48 51 3038 3041 O
following 52 61 3042 3051 O
criteria 62 70 3052 3060 O

For 0 3 3061 3064 O
patients 4 12 3065 3073 O
with 13 17 3074 3078 O
ITP 18 21 3079 3082 B-chronic_disease
( 22 23 3083 3084 I-chronic_disease
idiopathic 23 33 3084 3094 I-chronic_disease
thrombocytopenic 34 50 3095 3111 I-chronic_disease
purpura 51 58 3112 3119 I-chronic_disease
) 58 59 3119 3120 I-chronic_disease
or 60 62 3121 3123 O
AIHA 63 67 3124 3128 B-chronic_disease
( 68 69 3129 3130 I-chronic_disease
autoimmune 69 79 3130 3140 I-chronic_disease
hemolytic 80 89 3141 3150 I-chronic_disease
anemia 90 96 3151 3157 I-chronic_disease
) 96 97 3157 3158 I-chronic_disease
, 97 98 3158 3159 O
a 99 100 3160 3161 O
case 101 105 3162 3166 O
by 106 108 3167 3169 O
case 109 113 3170 3174 O
discussion 114 124 3175 3185 O
with 125 129 3186 3190 O
study 130 135 3191 3196 O
principal 136 145 3197 3206 O
investigator 146 158 3207 3219 O
( 159 160 3220 3221 O
PI 160 162 3221 3223 O
) 162 163 3223 3224 O
may 164 167 3225 3228 O
be 168 170 3229 3231 O
considered 171 181 3232 3242 O

Hemoglobin 0 10 3243 3253 B-clinical_variable
> 11 12 3254 3255 O
= 12 13 3255 3256 O
80 14 16 3257 3259 B-lower_bound
d 17 18 3260 3261 I-lower_bound
/ 18 19 3261 3262 I-lower_bound
L 19 20 3262 3263 I-lower_bound
( 21 22 3264 3265 O
or 22 24 3265 3267 O
> 25 26 3268 3269 O
= 26 27 3269 3270 O
8 28 29 3271 3272 B-lower_bound
g 30 31 3273 3274 I-lower_bound
/ 31 32 3274 3275 I-lower_bound
dL 32 34 3275 3277 I-lower_bound
) 34 35 3277 3278 O

History 0 7 3279 3286 O
of 8 10 3287 3289 O
allergic 11 19 3290 3298 O
reactions 20 29 3299 3308 O
attributed 30 40 3309 3319 O
to 41 43 3320 3322 O
compounds 44 53 3323 3332 O
of 54 56 3333 3335 O
similar 57 64 3336 3343 O
chemical 65 73 3344 3352 O
or 74 76 3353 3355 O
biologic 77 85 3356 3364 O
composition 86 97 3365 3376 O
to 98 100 3377 3379 O
MEDI-570 101 109 3380 3388 B-allergy_name
or 110 112 3389 3391 O
history 113 120 3392 3399 O
of 121 123 3400 3402 O
anaphylaxis 124 135 3403 3414 B-chronic_disease
to 136 138 3415 3417 O
any 139 142 3418 3421 O
biological 143 153 3422 3432 B-allergy_name
component 154 163 3433 3442 I-allergy_name

History 0 7 3443 3450 O
of 8 10 3451 3453 O
human 11 16 3454 3459 B-chronic_disease
immunodeficiency 17 33 3460 3476 I-chronic_disease
virus 34 39 3477 3482 I-chronic_disease
( 40 41 3483 3484 I-chronic_disease
HIV 41 44 3484 3487 I-chronic_disease
) 44 45 3487 3488 I-chronic_disease
infection 46 55 3489 3498 O
; 55 56 3498 3499 O
the 57 60 3500 3503 O
human 61 66 3504 3509 O
immunodeficiency 67 83 3510 3526 O
virus 84 89 3527 3532 O
( 90 91 3533 3534 O
HIV 91 94 3534 3537 O
) 94 95 3537 3538 O
depletes 96 104 3539 3547 O
CD4 105 108 3548 3551 O
T 109 110 3552 3553 O
- 110 111 3553 3554 O
cells 111 116 3554 3559 O
and 117 120 3560 3563 O
could 121 126 3564 3569 O
also 127 131 3570 3574 O
have 132 136 3575 3579 O
a 137 138 3580 3581 O
role 139 143 3582 3586 O
in 144 146 3587 3589 O
T 147 148 3590 3591 O
- 148 149 3591 3592 O
cell 149 153 3592 3596 O
anergy 154 160 3597 3603 O
; 160 161 3603 3604 O
since 162 167 3605 3610 O
MEDI-570 168 176 3611 3619 B-treatment
preferentially 177 191 3620 3634 O
affects 192 199 3635 3642 O
CD4 200 203 3643 3646 O
T 204 205 3647 3648 O
- 205 206 3648 3649 O
cell 206 210 3649 3653 O
numbers 211 218 3654 3661 O
and 219 222 3662 3665 O
function 223 231 3666 3674 O
, 231 232 3674 3675 O
and 233 236 3676 3679 O
the 237 240 3680 3683 O
resultant 241 250 3684 3693 O
immunosuppression 251 268 3694 3711 B-treatment
by 269 271 3712 3714 O
this 272 276 3715 3719 O
agent 277 282 3720 3725 O
can 283 286 3726 3729 O
be 287 289 3730 3732 O
prolonged 290 299 3733 3742 O
, 299 300 3742 3743 O
exposing 301 309 3744 3752 O
HIV 310 313 3753 3756 O
patients 314 322 3757 3765 O
to 323 325 3766 3768 O
MEDI-570 326 334 3769 3777 O
will 335 339 3778 3782 O
place 340 345 3783 3788 O
them 346 350 3789 3793 O
in 351 353 3794 3796 O
an 354 356 3797 3799 O
unnecessary 357 368 3800 3811 O
risk 369 373 3812 3816 O
of 374 376 3817 3819 O
developing 377 387 3820 3830 O
infections 388 398 3831 3841 B-chronic_disease
due 399 402 3842 3845 O
to 403 405 3846 3848 O
an 406 408 3849 3851 O
underlying 409 419 3852 3862 O
acquired 420 428 3863 3871 O
cellular 429 437 3872 3880 O
immunity 438 446 3881 3889 O
defect 447 453 3890 3896 O

History 0 7 3897 3904 O
of 8 10 3905 3907 O
primary 11 18 3908 3915 B-chronic_disease
immunodeficiency 19 35 3916 3932 I-chronic_disease

Leukocytes 0 10 3933 3943 B-clinical_variable
> 11 12 3944 3945 O
= 12 13 3945 3946 O
2000 14 18 3947 3951 B-lower_bound
/ 18 19 3951 3952 I-lower_bound
mcL 19 22 3952 3955 I-lower_bound

Leukocytes 0 10 3956 3966 B-clinical_variable
> 11 12 3967 3968 O
= 12 13 3968 3969 O
3,000 14 19 3970 3975 B-lower_bound
/ 19 20 3975 3976 I-lower_bound
mcL 20 23 3976 3979 I-lower_bound

Life 0 4 3980 3984 B-clinical_variable
expectancy 5 15 3985 3995 I-clinical_variable
of 16 18 3996 3998 O
greater 19 26 3999 4006 O
than 27 31 4007 4011 O
6 32 33 4012 4013 B-lower_bound
months 34 40 4014 4020 I-lower_bound

Major 0 5 4021 4026 B-treatment
surgery 6 13 4027 4034 I-treatment
within 14 20 4035 4041 O
30 21 23 4042 4044 B-upper_bound
days 24 28 4045 4049 I-upper_bound
prior 29 34 4050 4055 I-upper_bound
or 35 37 4056 4058 O
during 38 44 4059 4065 O
the 45 48 4066 4069 O
study 49 54 4070 4075 O
period 55 61 4076 4082 O

PLT 0 3 4083 4086 B-clinical_variable
> 4 5 4087 4088 O
= 5 6 4088 4089 O
50 7 9 4090 4092 B-lower_bound
000 10 13 4093 4096 I-lower_bound
/ 13 14 4096 4097 I-lower_bound
mcL 14 17 4097 4100 I-lower_bound

Participants 0 12 4101 4113 O
with 13 17 4114 4118 O
well 18 22 4119 4123 O
- 22 23 4123 4124 O
controlled 23 33 4124 4134 O
asthma 34 40 4135 4141 B-chronic_disease
and/or 41 47 4142 4148 O
mild 48 52 4149 4153 B-chronic_disease
allergic 53 61 4154 4162 I-chronic_disease
rhinitis 62 70 4163 4171 I-chronic_disease
( 71 72 4172 4173 O
seasonal 72 80 4173 4181 O
allergies 81 90 4182 4191 O
) 90 91 4191 4192 O

Patients 0 8 4193 4201 O
must 9 13 4202 4206 O
have 14 18 4207 4211 O
at 19 21 4212 4214 O
least 22 27 4215 4220 O
one 28 31 4221 4224 B-lower_bound
measurable 32 42 4225 4235 O
lesion 43 49 4236 4242 O
that 50 54 4243 4247 O
can 55 58 4248 4251 O
be 59 61 4252 4254 O
accurately 62 72 4255 4265 O
measured 73 81 4266 4274 O
with 82 86 4275 4279 O
spiral 87 93 4280 4286 B-treatment
computed 94 102 4287 4295 I-treatment
tomography 103 113 4296 4306 I-treatment
( 114 115 4307 4308 I-treatment
CT 115 117 4308 4310 I-treatment
) 117 118 4310 4311 I-treatment
scan 119 123 4312 4316 I-treatment
, 123 124 4316 4317 O
magnetic 125 133 4318 4326 B-treatment
resonance 134 143 4327 4336 I-treatment
imaging 144 151 4337 4344 I-treatment
( 152 153 4345 4346 I-treatment
MRI 153 156 4346 4349 I-treatment
) 156 157 4349 4350 I-treatment
scan 158 162 4351 4355 I-treatment
, 162 163 4355 4356 O
or 164 166 4357 4359 O
physical 167 175 4360 4368 O
exam 176 180 4369 4373 O
( 181 182 4374 4375 O
by 182 184 4375 4377 O
calipers 185 193 4378 4386 O
only 194 198 4387 4391 O
) 198 199 4391 4392 O
; 199 200 4392 4393 O
( 201 202 4394 4395 O
PTCL 202 206 4395 4399 B-cancer
, 206 207 4399 4400 O
AITL 208 212 4401 4405 B-cancer
and 213 216 4406 4409 O
follicular 217 227 4410 4420 B-cancer
lymphoma 228 236 4421 4429 I-cancer
patients 237 245 4430 4438 O
will 246 250 4439 4443 O
be 251 253 4444 4446 O
assessed 254 262 4447 4455 O
on 263 265 4456 4458 O
this 266 270 4459 4463 O
study 271 276 4464 4469 O
using 277 282 4470 4475 O
the 283 286 4476 4479 O
Lugano 287 293 4480 4486 O
criteria 294 302 4487 4495 O
for 303 306 4496 4499 O
the 307 310 4500 4503 O
evaluation 311 321 4504 4514 O
of 322 324 4515 4517 O
lymphomas 325 334 4518 4527 B-cancer
; 334 335 4527 4528 O
CTCL 336 340 4529 4533 B-cancer
and 341 344 4534 4537 O
MF 345 347 4538 4540 B-cancer
patients 348 356 4541 4549 O
will 357 361 4550 4554 O
be 362 364 4555 4557 O
assessed 365 373 4558 4566 O
using 374 379 4567 4572 O
International 380 393 4573 4586 O
Society 394 401 4587 4594 O
for 402 405 4595 4598 O
Cutaneous 406 415 4599 4608 O
Lymphomas 416 425 4609 4618 O
[ 426 427 4619 4620 O
ISCL 427 431 4620 4624 O
] 431 432 4624 4625 O
and 433 436 4626 4629 O
European 437 445 4630 4638 O
Organization 446 458 4639 4651 O
for 459 462 4652 4655 O
Research 463 471 4656 4664 O
and 472 475 4665 4668 O
Treatment 476 485 4669 4678 O
of 486 488 4679 4681 O
Cancer 489 495 4682 4688 O
[ 496 497 4689 4690 O
EORTC 497 502 4690 4695 O
criteria 503 511 4696 4704 O
] 511 512 4704 4705 O
) 512 513 4705 4706 O

Patients 0 8 4707 4715 O
must 9 13 4716 4720 O
not 14 17 4721 4724 O
have 18 22 4725 4729 O
received 23 31 4730 4738 O
a 32 33 4739 4740 O
transfusion 34 45 4741 4752 B-treatment
, 45 46 4752 4753 I-treatment
with 47 51 4754 4758 I-treatment
packed 52 58 4759 4765 I-treatment
red 59 62 4766 4769 I-treatment
blood 63 68 4770 4775 I-treatment
cells 69 74 4776 4781 I-treatment
, 74 75 4781 4782 O
within 76 82 4783 4789 O
2 83 84 4790 4791 B-upper_bound
weeks 85 90 4792 4797 I-upper_bound
prior 91 96 4798 4803 I-upper_bound
to 97 99 4804 4806 O
sample 100 106 4807 4813 O
being 107 112 4814 4819 O
collected 113 122 4820 4829 O

Patients 0 8 4830 4838 O
not 9 12 4839 4842 O
receiving 13 22 4843 4852 O
systemic 23 31 4853 4861 B-treatment
therapy 32 39 4862 4869 I-treatment
( 40 41 4870 4871 O
i.e. 41 45 4871 4875 O
, 45 46 4875 4876 O
systemic 47 55 4877 4885 B-treatment
steroids 56 64 4886 4894 I-treatment
or 65 67 4895 4897 O
biologic 68 76 4898 4906 B-treatment
therapy 77 84 4907 4914 I-treatment
with 85 89 4915 4919 O
disease 90 97 4920 4927 B-treatment
modifying 98 107 4928 4937 I-treatment
anti 108 112 4938 4942 I-treatment
- 112 113 4942 4943 I-treatment
rheumatic 113 122 4943 4952 I-treatment
drugs 123 128 4953 4958 I-treatment
[ 129 130 4959 4960 I-treatment
DMARDs 130 136 4960 4966 I-treatment
] 136 137 4966 4967 I-treatment
) 137 138 4967 4968 O
within 139 145 4969 4975 O
2 146 147 4976 4977 B-upper_bound
years 148 153 4978 4983 I-upper_bound

Patients 0 8 4984 4992 O
who 9 12 4993 4996 O
are 13 16 4997 5000 O
receiving 17 26 5001 5010 O
any 27 30 5011 5014 O
other 31 36 5015 5020 O
investigational 37 52 5021 5036 B-treatment
agents 53 59 5037 5043 I-treatment

Patients 0 8 5044 5052 O
who 9 12 5053 5056 O
have 13 17 5057 5061 O
undergone 18 27 5062 5071 O
allogeneic 28 38 5072 5082 B-treatment
stem 39 43 5083 5087 I-treatment
cell 44 48 5088 5092 I-treatment
transplantation 49 64 5093 5108 I-treatment

Patients 0 8 5109 5117 O
who 9 12 5118 5121 O
have 13 17 5122 5126 O
undergone 18 27 5127 5136 O
autologous 28 38 5137 5147 B-treatment
stem 39 43 5148 5152 I-treatment
cell 44 48 5153 5157 I-treatment
transplantation 49 64 5158 5173 I-treatment
within 65 71 5174 5180 O
3 72 73 5181 5182 B-upper_bound
months 74 80 5183 5189 I-upper_bound
from 81 85 5190 5194 O
study 86 91 5195 5200 O
entry 92 97 5201 5206 O

Patients 0 8 5207 5215 O
with 9 13 5216 5220 O
a 14 15 5221 5222 O
weight 16 22 5223 5229 B-clinical_variable
of 23 25 5230 5232 O
< 26 27 5233 5234 O
39 28 30 5235 5237 B-upper_bound
kg 31 33 5238 5240 I-upper_bound

Patients 0 8 5241 5249 O
with 9 13 5250 5254 O
active 14 20 5255 5261 O
, 20 21 5261 5262 O
known 22 27 5263 5268 O
, 27 28 5268 5269 O
or 29 31 5270 5272 O
suspected 32 41 5273 5282 O
autoimmune 42 52 5283 5293 B-chronic_disease
disease 53 60 5294 5301 I-chronic_disease

Patients 0 8 5302 5310 O
with 9 13 5311 5315 O
confirmed 14 23 5316 5325 O
diagnosis 24 33 5326 5335 O
of 34 36 5336 5338 O
peripheral 37 47 5339 5349 B-cancer
T 48 49 5350 5351 I-cancer
- 49 50 5351 5352 I-cancer
cell 50 54 5352 5356 I-cancer
lymphoma 55 63 5357 5365 I-cancer
( 64 65 5366 5367 I-cancer
PTCL 65 69 5367 5371 I-cancer
) 69 70 5371 5372 I-cancer
follicular 71 81 5373 5383 O
type 82 86 5384 5388 O
or 87 89 5389 5391 O
angioimmunoblastic 90 108 5392 5410 B-cancer
T 109 110 5411 5412 I-cancer
- 110 111 5412 5413 I-cancer
cell 111 115 5413 5417 I-cancer
lymphoma 116 124 5418 5426 I-cancer
( 125 126 5427 5428 I-cancer
AITL 126 130 5428 5432 I-cancer
) 130 131 5432 5433 I-cancer
that 132 136 5434 5438 O
is 137 139 5439 5441 O
refractory 140 150 5442 5452 O
to 151 153 5453 5455 O
at 154 156 5456 5458 O
least 157 162 5459 5464 O
one 163 166 5465 5468 B-lower_bound
line 167 171 5469 5473 O
of 172 174 5474 5476 O
therapy 175 182 5477 5484 B-treatment

Patients 0 8 5485 5493 O
with 9 13 5494 5498 O
known 14 19 5499 5504 O
brain 20 25 5505 5510 B-cancer
metastases 26 36 5511 5521 I-cancer
should 37 43 5522 5528 O
be 44 46 5529 5531 O
excluded 47 55 5532 5540 O
from 56 60 5541 5545 O
this 61 65 5546 5550 O
clinical 66 74 5551 5559 O
trial 75 80 5560 5565 O
because 81 88 5566 5573 O
of 89 91 5574 5576 O
their 92 97 5577 5582 O
poor 98 102 5583 5587 O
prognosis 103 112 5588 5597 O
and 113 116 5598 5601 O
because 117 124 5602 5609 O
they 125 129 5610 5614 O
often 130 135 5615 5620 O
develop 136 143 5621 5628 O
progressive 144 155 5629 5640 O
neurologic 156 166 5641 5651 O
dysfunction 167 178 5652 5663 O
that 179 183 5664 5668 O
would 184 189 5669 5674 O
confound 190 198 5675 5683 O
the 199 202 5684 5687 O
evaluation 203 213 5688 5698 O
of 214 216 5699 5701 O
neurologic 217 227 5702 5712 O
and 228 231 5713 5716 O
other 232 237 5717 5722 O
adverse 238 245 5723 5730 O
events 246 252 5731 5737 O

Platelets 0 9 5738 5747 B-clinical_variable
( 10 11 5748 5749 I-clinical_variable
PLT 11 14 5749 5752 I-clinical_variable
) 14 15 5752 5753 I-clinical_variable
> 16 17 5754 5755 O
= 17 18 5755 5756 O
50,000 19 25 5757 5763 B-lower_bound
/ 25 26 5763 5764 I-lower_bound
mcL 26 29 5764 5767 I-lower_bound

Receipt 0 7 5768 5775 O
of 8 10 5776 5778 O
live 11 15 5779 5783 O
or 16 18 5784 5786 O
live 19 23 5787 5791 O
attenuated 24 34 5792 5802 B-treatment
vaccine 35 42 5803 5810 I-treatment
within 43 49 5811 5817 O
12 50 52 5818 5820 B-upper_bound
weeks 53 58 5821 5826 I-upper_bound
prior 59 64 5827 5832 I-upper_bound
to 65 67 5833 5835 O
enrollment 68 78 5836 5846 O

Relapsed 0 8 5847 5855 O
or 9 11 5856 5858 O
refractory 12 22 5859 5869 O
post 23 27 5870 5874 B-treatment
autologous 28 38 5875 5885 I-treatment
cell 39 43 5886 5890 I-treatment
transplantation 44 59 5891 5906 I-treatment
( 60 61 5907 5908 I-treatment
HCT 61 64 5908 5911 I-treatment
) 64 65 5911 5912 I-treatment

Relapsed 0 8 5913 5921 O
or 9 11 5922 5924 O
refractory 12 22 5925 5935 O
to 23 25 5936 5938 O
at 26 28 5939 5941 O
least 29 34 5942 5947 O
2 35 36 5948 5949 B-lower_bound
lines 37 42 5950 5955 O
of 43 45 5956 5958 O
therapy 46 53 5959 5966 B-treatment
AND 54 57 5967 5970 O

Residual 0 8 5971 5979 O
hypothyroidism 9 23 5980 5994 B-chronic_disease
due 24 27 5995 5998 O
to 28 30 5999 6001 O
autoimmune 31 41 6002 6012 B-chronic_disease
condition 42 51 6013 6022 I-chronic_disease
only 52 56 6023 6027 O
requiring 57 66 6028 6037 O
hormone 67 74 6038 6045 B-treatment
replacement 75 86 6046 6057 I-treatment

The 0 3 6058 6061 O
effects 4 11 6062 6069 O
of 12 14 6070 6072 O
MEDI-570 15 23 6073 6081 B-treatment
on 24 26 6082 6084 O
the 27 30 6085 6088 O
developing 31 41 6089 6099 O
human 42 47 6100 6105 O
fetus 48 53 6106 6111 O
are 54 57 6112 6115 O
unknown 58 65 6116 6123 O
; 65 66 6123 6124 O
for 67 70 6125 6128 O
this 71 75 6129 6133 O
reason 76 82 6134 6140 O
, 82 83 6140 6141 O
women 84 89 6142 6147 B-gender
of 90 92 6148 6150 O
child 93 98 6151 6156 O
- 98 99 6156 6157 O
bearing 99 106 6157 6164 O
potential 107 116 6165 6174 O
and 117 120 6175 6178 O
men 121 124 6179 6182 O
must 125 129 6183 6187 O
agree 130 135 6188 6193 B-contraception_consent
to 136 138 6194 6196 I-contraception_consent
use 139 142 6197 6200 I-contraception_consent
adequate 143 151 6201 6209 I-contraception_consent
contraception 152 165 6210 6223 I-contraception_consent
( 166 167 6224 6225 O
hormonal 167 175 6225 6233 B-contraception_consent
or 176 178 6234 6236 O
barrier 179 186 6237 6244 B-contraception_consent
method 187 193 6245 6251 I-contraception_consent
of 194 196 6252 6254 I-contraception_consent
birth 197 202 6255 6260 I-contraception_consent
control 203 210 6261 6268 I-contraception_consent
; 210 211 6268 6269 O
abstinence 212 222 6270 6280 B-contraception_consent
) 222 223 6280 6281 O
prior 224 229 6282 6287 O
to 230 232 6288 6290 O
study 233 238 6291 6296 O
entry 239 244 6297 6302 O
, 244 245 6302 6303 O
during 246 252 6304 6310 O
the 253 256 6311 6314 O
study 257 262 6315 6320 O
participation 263 276 6321 6334 O
, 276 277 6334 6335 O
and 278 281 6336 6339 O
for 282 285 6340 6343 O
3 286 287 6344 6345 B-upper_bound
months 288 294 6346 6352 I-upper_bound
after 295 300 6353 6358 I-upper_bound
the 301 304 6359 6362 O
last 305 309 6363 6367 O
dose 310 314 6368 6372 O
of 315 317 6373 6375 O
the 318 321 6376 6379 O
drug 322 326 6380 6384 O
; 326 327 6384 6385 O
should 328 334 6386 6392 O
a 335 336 6393 6394 O
woman 337 342 6395 6400 B-gender
become 343 349 6401 6407 O
pregnant 350 358 6408 6416 B-pregnancy
or 359 361 6417 6419 O
suspect 362 369 6420 6427 O
she 370 373 6428 6431 O
is 374 376 6432 6434 O
pregnant 377 385 6435 6443 O
while 386 391 6444 6449 O
she 392 395 6450 6453 O
or 396 398 6454 6456 O
her 399 402 6457 6460 O
partner 403 410 6461 6468 O
is 411 413 6469 6471 O
participating 414 427 6472 6485 O
in 428 430 6486 6488 O
this 431 435 6489 6493 O
study 436 441 6494 6499 O
, 441 442 6499 6500 O
she 443 446 6501 6504 O
should 447 453 6505 6511 O
inform 454 460 6512 6518 O
her 461 464 6519 6522 O
treating 465 473 6523 6531 O
physician 474 483 6532 6541 O
immediately 484 495 6542 6553 O

Total 0 5 6554 6559 B-clinical_variable
bilirubin 6 15 6560 6569 I-clinical_variable
< 16 17 6570 6571 O
1.5 18 21 6572 6575 B-upper_bound
upper 22 27 6576 6581 I-upper_bound
limit 28 33 6582 6587 I-upper_bound
of 34 36 6588 6590 I-upper_bound
normal 37 43 6591 6597 I-upper_bound
( 44 45 6598 6599 I-upper_bound
ULN 45 48 6599 6602 I-upper_bound
) 48 49 6602 6603 I-upper_bound

Type 0 4 6604 6608 B-chronic_disease
1 5 6 6609 6610 I-chronic_disease
diabetes 7 15 6611 6619 I-chronic_disease
mellitus 16 24 6620 6628 I-chronic_disease

Uncontrolled 0 12 6629 6641 O
intercurrent 13 25 6642 6654 O
illness 26 33 6655 6662 O
including 34 43 6663 6672 O
, 43 44 6672 6673 O
but 45 48 6674 6677 O
not 49 52 6678 6681 O
limited 53 60 6682 6689 O
to 61 63 6690 6692 O
, 63 64 6692 6693 O
ongoing 65 72 6694 6701 O
or 73 75 6702 6704 O
active 76 82 6705 6711 B-chronic_disease
infection 83 92 6712 6721 I-chronic_disease
, 92 93 6721 6722 O
symptomatic 94 105 6723 6734 O
congestive 106 116 6735 6745 B-chronic_disease
heart 117 122 6746 6751 I-chronic_disease
failure 123 130 6752 6759 I-chronic_disease
, 130 131 6759 6760 O
unstable 132 140 6761 6769 O
angina 141 147 6770 6776 B-chronic_disease
pectoris 148 156 6777 6785 I-chronic_disease
, 156 157 6785 6786 O
cardiac 158 165 6787 6794 B-chronic_disease
arrhythmia 166 176 6795 6805 I-chronic_disease
, 176 177 6805 6806 O
or 178 180 6807 6809 O
psychiatric 181 192 6810 6821 B-chronic_disease
illness 193 200 6822 6829 I-chronic_disease
/ 200 201 6829 6830 I-chronic_disease
social 201 207 6830 6836 I-chronic_disease
situations 208 218 6837 6847 I-chronic_disease
that 219 223 6848 6852 O
would 224 229 6853 6858 O
limit 230 235 6859 6864 O
compliance 236 246 6865 6875 O
with 247 251 6876 6880 O
study 252 257 6881 6886 O
requirements 258 270 6887 6899 O

Vitiligo 0 8 6900 6908 B-chronic_disease

anaplastic 0 10 6909 6919 B-cancer
large 11 16 6920 6925 I-cancer
cell 17 21 6926 6930 I-cancer
lymphoma 22 30 6931 6939 I-cancer
( 31 32 6940 6941 I-cancer
ALCL 32 36 6941 6945 I-cancer
) 36 37 6945 6946 I-cancer
and 38 41 6947 6950 O
natural 42 49 6951 6958 O
killer 50 56 6959 6965 O
T 57 58 6966 6967 B-cancer
- 58 59 6967 6968 I-cancer
cell 59 63 6968 6972 I-cancer
lymphoma 64 72 6973 6981 I-cancer
nasal 73 78 6982 6987 I-cancer
type 79 83 6988 6992 I-cancer
( 84 85 6993 6994 I-cancer
NKTCL 85 90 6994 6999 I-cancer
) 90 91 6999 7000 I-cancer

men 0 3 7001 7004 B-gender
treated 4 11 7005 7012 O
or 12 14 7013 7015 O
enrolled 15 23 7016 7024 O
on 24 26 7025 7027 O
this 27 31 7028 7032 O
protocol 32 40 7033 7041 O
must 41 45 7042 7046 O
have 46 50 7047 7051 O
either 51 57 7052 7058 O
had 58 61 7059 7062 O
a 62 63 7063 7064 O
prior 64 69 7065 7070 B-treatment
vasectomy 70 79 7071 7080 I-treatment
or 80 82 7081 7083 O
agree 83 88 7084 7089 B-contraception_consent
to 89 91 7090 7092 I-contraception_consent
use 92 95 7093 7096 I-contraception_consent
effective 96 105 7097 7106 I-contraception_consent
contraception 106 119 7107 7120 I-contraception_consent
prior 120 125 7121 7126 O
to 126 128 7127 7129 O
the 129 132 7130 7133 O
study 133 138 7134 7139 O
, 138 139 7139 7140 O
during 140 146 7141 7147 O
the 147 150 7148 7151 O
study 151 156 7152 7157 O
, 156 157 7157 7158 O
and 158 161 7159 7162 O
for 162 165 7163 7166 O
3 166 167 7167 7168 B-upper_bound
months 168 174 7169 7175 I-upper_bound
after 175 180 7176 7181 I-upper_bound
the 181 184 7182 7185 O
last 185 189 7186 7190 O
dose 190 194 7191 7195 O
of 195 197 7196 7198 O
the 198 201 7199 7202 O
drug 202 206 7203 7207 O
; 206 207 7207 7208 O
males 208 213 7209 7214 B-gender
should 214 220 7215 7221 O
avoid 221 226 7222 7227 O
fathering 227 236 7228 7237 O
children 237 245 7238 7246 O
during 246 252 7247 7253 O
and 253 256 7254 7257 O
for 257 260 7258 7261 O
at 261 263 7262 7264 O
least 264 269 7265 7270 O
three 270 275 7271 7276 B-lower_bound
months 276 282 7277 7283 I-lower_bound
after 283 288 7284 7289 I-lower_bound
therapy 289 296 7290 7297 B-treatment
is 297 299 7298 7300 O
completed 300 309 7301 7310 O

